RT Journal Article
SR Electronic
T1 The basic reproduction number and prediction of the epidemic size of the novel coronavirus (COVID-19) in Shahroud, Iran
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.04.20052308
DO 10.1101/2020.04.04.20052308
A1 Khosravi, Ahmad
A1 Chaman, Reza
A1 Rohani-Rasaf, Marzieh
A1 Zare, Fariba
A1 Mehravaran, Shiva
A1 Emamian, Mohammad Hassan
YR 2020
UL http://medrxiv.org/content/early/2020/04/08/2020.04.04.20052308.abstract
AB Objectives To estimate the basic reproduction number (R0) of COVID-19 in the early stage of the epidemic and predict the expected number of new cases in Shahroud, Northeast of Iran.Methods The R0 of COVID-19 was estimated using the serial interval distribution and the number of incidence cases. The serial interval was fit with a gamma distribution. The probable incidence and cumulative incidence in the next 30 days were predicted using the assumption that daily incidence follows a Poisson distribution determined by daily infectiousness. Data analysis was done using “earlyR” and “projections” packages in R software.Results The maximum-likelihood value of R0 was 2.7 (95% confidence interval (CI): 2.1 to 3.4) for the COVID-19 epidemic in the early 14 days and decreased to 1.13 (95% CI: 1.03 to 1.25) by the end of the day 41. The expected average number of new cases in Shahroud is 9.0±3.8 case/day, which means an estimated total of 271 (95% CI: 178-383) new cases in the next 30 days.Conclusions It is essential to reduce the R0 to values below one. Therefore, we strongly recommend enforcing and continuing the current preventive measures, restricting travel, and providing screening tests for a larger proportion of the population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Shahroud University of Medical Sciences (Grant No. 98126).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request